CN109259908A - A kind of novel load medicine airway stent and preparation method thereof - Google Patents
A kind of novel load medicine airway stent and preparation method thereof Download PDFInfo
- Publication number
- CN109259908A CN109259908A CN201811123256.6A CN201811123256A CN109259908A CN 109259908 A CN109259908 A CN 109259908A CN 201811123256 A CN201811123256 A CN 201811123256A CN 109259908 A CN109259908 A CN 109259908A
- Authority
- CN
- China
- Prior art keywords
- airway
- drug
- tube body
- support tube
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 114
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 52
- 239000000463 material Substances 0.000 claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims abstract description 23
- 239000002131 composite material Substances 0.000 claims abstract description 22
- 239000002270 dispersing agent Substances 0.000 claims abstract description 7
- 238000013461 design Methods 0.000 claims abstract description 6
- 238000010146 3D printing Methods 0.000 claims description 34
- 238000002844 melting Methods 0.000 claims description 14
- 230000008018 melting Effects 0.000 claims description 14
- 229920001610 polycaprolactone Polymers 0.000 claims description 13
- 239000004632 polycaprolactone Substances 0.000 claims description 13
- 230000000259 anti-tumor effect Effects 0.000 claims description 12
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 11
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000004626 polylactic acid Substances 0.000 claims description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 229920002988 biodegradable polymer Polymers 0.000 claims description 5
- 239000004621 biodegradable polymer Substances 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical group COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 4
- 229960004176 aclarubicin Drugs 0.000 claims description 4
- 229960003687 alizapride Drugs 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 150000003057 platinum Chemical class 0.000 claims description 4
- 230000026683 transduction Effects 0.000 claims description 4
- 238000010361 transduction Methods 0.000 claims description 4
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 2
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- WPGUUPJOAVPZBQ-UHFFFAOYSA-N [Cl].OP(O)(O)=O Chemical compound [Cl].OP(O)(O)=O WPGUUPJOAVPZBQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229950005951 azasetron Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 108700004675 bleomycetin Proteins 0.000 claims description 2
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229960002448 dasatinib Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004635 mesna Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229950007221 nedaplatin Drugs 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229940120982 tarceva Drugs 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 239000004711 α-olefin Substances 0.000 claims description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 1
- 190000005734 Nedaplatin Chemical compound 0.000 claims 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000007334 copolymerization reaction Methods 0.000 claims 1
- 229960005343 ondansetron Drugs 0.000 claims 1
- 229920001169 thermoplastic Polymers 0.000 claims 1
- 239000004416 thermosoftening plastic Substances 0.000 claims 1
- 229920001567 vinyl ester resin Polymers 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 abstract description 6
- 206010036790 Productive cough Diseases 0.000 abstract description 5
- 210000004081 cilia Anatomy 0.000 abstract description 4
- 238000002513 implantation Methods 0.000 abstract description 4
- 238000006073 displacement reaction Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000011148 porous material Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 17
- 238000002591 computed tomography Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 206010003598 Atelectasis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920004933 Terylene® Polymers 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000002517 constrictor effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 230000005801 respiratory difficulty Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention belongs to the field of medical instrument technology, a kind of novel load medicine airway stent and preparation method thereof is specifically disclosed.The novel load medicine airway stent includes support tube body, and hole is arranged in the surface of the support tube body, and the inside of described hole is mounted with drug/polymer composite, and the end face design of the support tube body has buckle structure；Drug/the polymer composite is grouped as by group as follows by mass percentage: drug 2%-20%, high molecular material 75%-97.8%, dispersing agent 0.2%-5%.Support tube body in the application can be designed and prepare according to the air flue feature of patient, more preferable with patient airway matching after implantation air flue, and avoiding the occurrence of displacement influences therapeutic effect；The problems such as drug load inside hole is less than pore volume, can provide playground for airway surface cilium, avoids overlay film frame that airway surface ciliary movement is hindered to cause air flue discomfort or unsmooth expectoration.
Description
Technical field
The invention belongs to the field of medical instrument technology, in particular to a kind of novel load medicine airway stent and preparation method thereof.
The bracket has " C " type structure, has the function of to carry medicine, can be used for expanding narrow air flue and inhibits air flue restenosis.
Background technique
Chronic Obstructive Pulmonary Disease (COPD, chronic obstructive pulmonary disease) is that persistently existing respiratory symptom and air-flow are limited as feature
Chronic disease, airway constriction are the most apparent pathological change features of patients with COPD air flue.Usual air flue luminal stenosis is more than
50% is likely to occur apparent clinical symptoms, as lumen diameter≤10mm, then will appear the expiratory dyspnea of serious labour's property, when
It may occur in which the expiratory dyspnea of tranquillization when lumen diameter≤5mm.Occur airway constriction after, secondary narrow section distal end it is obstructive
Pulmonary emphysema, obstructive pneumonia or obstructive atelectasis, cause patient apparent unsmooth breath symptom occur, such as swash property cough, cough
Phlegm is powerless and chest blocks up uncomfortable in chest etc., can cause severe expiratory dyspnea, respiratory failure even dead when narrow serious, seriously threaten patient
Life security.Airway constriction clinically can be released frequently with the methods of tracheotomy, intubation or implantation bracket, it is raw to save patient
Life.
Stenter to implant is quick and one of the effective ways for alleviating airway constriction patient respiratory difficulty, is a kind of emerging minimally invasive
Therapy has been increasingly becoming the prefered method for the treatment of air flue benign stricture in recent years.However, existing metal airway stent is to gas
Road stimulation is big, and there are blood coagulation complication, flexibilitys to mismatch, metallic foreign body permanently retains in and occurs in vivo with in-stent restenosis
The defects of rate is high.Precoated metal bracket is that special film property material (polytetrafluoroethylene (PTFE), terylene, polyester, poly- ammonia are coated on metallic support
Base Ethyl formate etc.) bracket, not only remained the function of metallic support, but also the characteristic with film property material, bare metal can be overcome
Bracket has that tumour and granulation grow into intracavitary and lead to restenosis.However, after air flue is capped, the ciliary movement of mucous membrane
It is suppressed, it is easy to cause expectoration difficulties.
There are biodegradable characteristics using the airway stent such as polylactic acid, polycaprolactone etc. of high molecular material preparation, it can
Overcome the shortcomings of that metallic support foreign matter is permanently retained；Have biocompatibility excellent using silicon stent, elasticity is good etc. excellent
Point.However, the airway stent of existing extrusion and the above-mentioned polymer base material of mold shaping method preparation, shape, caliber base
This is fixed, and is unable to satisfy the different individual demand of different patient airways, displacement problem clinically occurs, curative effect is caused to become
Difference.
Summary of the invention
The primary purpose of the present invention is that overcoming shortcoming and deficiency existing in the prior art, a kind of novel load medicine gas is provided
Road bracket, the bracket have the function of " C " type structure, have load medicine, can be used for expanding narrow air flue and inhibit air flue restenosis.
A further object of the present invention is to provide the preparation methods of the novel load medicine airway stent.
The purpose of the invention is achieved by the following technical solution:
Hole, institute is arranged in the surface of a kind of novel load medicine airway stent, including support tube body, the support tube body
The inside for stating hole is mounted with drug/polymer composite, and the end face design of the support tube body has buckle structure；The medicine
Object/polymer composite is grouped as by group as follows by mass percentage: drug 2%-20%, high molecular material 75%-
97.8%, dispersing agent 0.2%-5%.
In one of them embodiment, the support tube body unclosed, tubulose with a thickness of 1-3mm for " C " type
Object.
In one of them embodiment, the surface of the support tube body is provided with the hole being not penetrated, described hole
Depth be the support tube body thickness 60%-80%.
In one of them embodiment, the support tube body uses Biodegradable polymer material and/or non-drop
Solution property high molecular material is prepared.
In one of them embodiment, the Biodegradable polymer material is thermoplasticity, biodegradable high score
One of sub- material, preferably polylactic acid (PLA), polycaprolactone (PCL) and poly lactide-glycolide acid (PLGA) or
At least two mixture.
In one of them embodiment, the nondegradation high molecular material is thermoplasticity, nondegradation macromolecule material
Material, preferably polyurethane (TPU), ethylene vinyl acetate copolymer (EVA), vinyl-acrylate copolymer (EMA) and second
One of alkene-alpha olefin copolymer (POE).
In one of them embodiment, one end of the support tube body is provided with location hole, the support tube body
Other end be provided with positioning pin, the positioning pin is inserted into the location hole and forms the buckle structure.Such as when described novel
After carrying medicine airway stent implantation patient airway, by supporting device struts positioning pin is inserted into location hole, formation one is closed
Tube expands air flue and is played a supporting role.
In one of them embodiment, the useful load of the drug/polymer composite is the volume of described hole
70%-80%.The drug loaded inside hole discharges drug by migration effect, and drug load is less than pore volume, can be
Airway surface cilium provides playground, avoids overlay film frame that airway surface ciliary movement is hindered to cause air flue discomfort or expectoration not
The problems such as smooth.
In one of them embodiment, the melting temperature of the high molecular material or softening temperature≤70 DEG C, melt flow
Dynamic index >=20g/10min (test temperature: 190 DEG C, load 2.16kg), preferably ethylene vinyl acetate copolymer (EVA)
Or polycaprolactone (PCL).
In one of them embodiment, the drug is antitumor platinum class, interference transcription and RNA is prevented to synthesize
Drug, antibiotic, anti-signal transduction medicine, one of antitumor adjuvant and anti-tumour antibody medicine or at least two mixing
Object.
In one of them embodiment, the antitumor platinum class is preferably oxaliplatin, carboplatin or Nedaplatin.
In one of them embodiment, the interference transcription and the drug for preventing RNA from synthesizing are preferably A Rou ratio
Star, Doxorubicin or mitoxantrone.
In one of them embodiment, the antibiotic is preferably bleomycin, bleomycin A5 or mitomycin.
In one of them embodiment, the anti-signal transduction medicine is preferably Tarceva, Gefitinib, Imatinib
Or Dasatinib.
In one of them embodiment, the antitumor adjuvant is preferably alizapride, Azasetron, Ang Dansi
Fine jade, chlorine phosphoric acid or mesna.
In one of them embodiment, the anti-tumour antibody medicine is preferably Rituximab, ibritumomab tiuxetan, western appropriate
Former times monoclonal antibody or bevacizumab.In one of them embodiment, the dispersing agent be preferably polyethylene glycol (PEG-1000) or/and
Poloxamer (such as 188,407).
In one of them embodiment, the drug/polymer composite is prepared with the following method: by drug
2%-20%, high molecular material 75%-97.8% and dispersing agent 0.2%-5% are uniformly mixed, and carry out melting altogether in 60-80 DEG C
It is mixed, then cylindrical body is hot pressed into 60-85 DEG C；The percentage is mass percent.
The preparation method of the novel load medicine airway stent includes the following steps: to obtain gas firstly, scan patient airway
The airway images are converted to 3D digital figure by 3D-MAX software by road image, are designed according to the 3D digital figure new
The 3D printing model of type load medicine airway stent；Then, by polylactic acid drying, heating melting, 3D printing wire rod is prepared；Then, it adopts
The 3D printing wire rod is printed into the tube body that is supported with 3D melt-blown (FDM) printer；Finally, drug/macromolecule is compound
Object is packed into the inside of the hole of the support tube body, obtains novel load medicine airway stent.
Compared with existing extrusion and the airway stent of mold shaping method preparation, the present invention has compared with the existing technology
Following advantage and effect:
(1) the support tube body in the application can be designed and prepare according to the air flue feature of patient, after being implanted into air flue
More preferable with patient airway matching, avoiding the occurrence of displacement influences therapeutic effect；
(2) it is loaded with drug in the reserved hole in the surface of the support tube body in the application, passes through drug and bracket
Support synergistic effect, obtains better treatment of airway constriction effect；
(3) drug loaded inside hole discharges drug by migration effect, and drug load is less than bore hole size, can
Playground is provided for airway surface cilium, avoids overlay film frame that airway surface ciliary movement is hindered to cause air flue uncomfortable or expectoration
The problems such as unsmooth.
Detailed description of the invention
Fig. 1 is a kind of structural schematic diagram of novel load medicine airway stent provided by the invention；
Fig. 2 is the buckle structure schematic diagram of the novel load medicine airway stent of Fig. 1；
Fig. 3 is the preparation method flow diagram of the novel load medicine airway stent of Fig. 1.
Specific embodiment
Below with reference to embodiment and attached drawing, the present invention is described in further detail, but embodiments of the present invention are unlimited
In this.
Unless otherwise defined, all technical and scientific terms used herein belong to the skill of the technical field of the application
The normally understood meaning of art personnel is identical.Used term is intended merely to description specific embodiment in the description herein
Purpose, it is not intended that in limitation the application.
As shown in Figure 1, a kind of novel load medicine airway stent, described including supporting tube body 1 (3D printing polymer-based)
Support the surface of tube body 1 that hole 2 is set, the inside of described hole 2 is mounted with load medicinal gel, the support tube body 1
End face design has buckle structure 3.
The support tube body 1 is that " C " type is unclosed, tube with a thickness of 1-3mm, in the present embodiment with a thickness of
2mm。
The surface of the support tube body 1 is provided with the hole being not penetrated, and the depth of described hole 2 is the support tube sheet
The 60%-80% of 1 thickness of body, in the present embodiment, the depth of hole is 1.5mm.
As shown in Fig. 2, one end of the support tube body 1 is provided with location hole 31, it is described to support other the one of tube body 1
End is provided with positioning pin 32, and the positioning pin 32 is inserted into the location hole 31 and forms the buckle structure 3.Such as when the novel load
After medicine airway stent is implanted into patient airway, by supporting device struts positioning pin is inserted into location hole, a closed pipe is formed
Shape object, expands air flue and is played a supporting role.
It should be noted that the useful load of the drug/polymer composite is less than the volume of described hole.Inside hole
The drug of loading discharges drug by migration effect, and drug load is less than bore hole size, can provide work for airway surface cilium
The problems such as moving place, avoiding overlay film frame that airway surface ciliary movement is hindered to cause air flue discomfort or unsmooth expectoration.
The preparation method of the novel load medicine airway stent includes the following steps: firstly, using CT scan patient airway,
Airway images are obtained, the airway images are converted to by 3D digital figure by 3D-MAX software, according to the 3D digital figure
Design the 3D printing model of novel load medicine airway stent；Then, by polylactic acid drying, heating melting, 3D printing wire rod is prepared；It connects
, the 3D printing wire rod is printed by the tube body that is supported using 3D melt-blown (FDM) printer；Finally, by drug/macromolecule
Compound is packed into the inside of the hole of the support tube body, obtains novel load medicine airway stent.The signal of preparation method process
Figure is as shown in Figure 3.
Novel load medicine airway stent of the present invention is a kind of composite tube instrument that " C " type is unclosed, is crimped
It forms the smaller tube of diameter and patient airway stenosis is implanted by pusher.After implantation, clamping buckle structure, support tube
Ontology is played a supporting role, and surface hole defect plays loading drug effect.The present invention can expand air flue by mechanical expansion effect and cut
Face, prevent tumor tissues to Intracavity, provide certain space for the ciliary movement of airway surface the effects of.It is narrow in benign air flue
Narrow field is with a wide range of applications.
Embodiment 1
Firstly, using CT scan patient airway structure, airway images are obtained, by 3D-MAX software by the airway images
3D digital figure is converted to, the 3D printing model of novel load medicine airway stent is designed according to the 3D digital figure；Then, it will use
EVA (VA content is 18%, melt flow index 20g/10min) heating melting, prepares 3D printing wire rod；Then, using 3D
The 3D printing wire rod is printed the tube body that is supported by melt-blown (FDM) printer；
The EVA for accurately weighing the taxol of 2g, PEG-1000,97.5g of 0.5g, in the torque rheometer of temperature 70 C
It is blended, prepares drug/high molecular material compound；Above-mentioned compound is hot pressed into the hot press that temperature is 80 DEG C
It is cylindric.
Drug/polymer composite is packed into inside the reserving hole of support tube body, obtains novel load medicine airway stent.
Embodiment 2
Firstly, using CT scan patient airway structure, airway images are obtained, by 3D-MAX software by the airway images
3D digital figure is converted to, the 3D printing model of novel load medicine airway stent is designed according to the 3D digital figure；Then, it will use
EVA (VA content is 22%, melt flow index 30g/10min) heating melting, prepares 3D printing wire rod；Then, using 3D
The 3D printing wire rod is printed the tube body that is supported by melt-blown (FDM) printer；
Accurately weigh the mitomycin of 10g, the PLURONICS F87 of 3g, 60g EMA, 27g EVA, at 80 DEG C of temperature
It is blended in torque rheometer, prepares drug/high molecular material compound；By above-mentioned compound in heat at a temperature of 90 °C
It is hot pressed into press cylindric.
Drug/polymer composite is packed into inside the reserving hole of support tube body, obtains novel load medicine airway stent.
Embodiment 3
Firstly, using CT scan patient airway structure, airway images are obtained, by 3D-MAX software by the airway images
3D digital figure is converted to, the 3D printing model of novel load medicine airway stent is designed according to the 3D digital figure；Then, it will use
POE (melt flow index 20g/10min) heating melting prepares 3D printing wire rod；Then, using 3D melt-blown (FDM) printing
The 3D printing wire rod is printed the tube body that is supported by machine；
The POE for accurately weighing the Aclarubicin of 10g, 10g mitomycin, the poloxamer188 of 5g, 75g, at 65 DEG C of temperature
Torque rheometer in be blended, prepare drug/high molecular material compound；It in temperature is 70 DEG C by above-mentioned compound
It is hot pressed into hot press cylindric.
Drug/polymer composite is packed into inside the reserving hole of support tube body, obtains novel load medicine airway stent.
Embodiment 4
Firstly, using CT scan patient airway structure, airway images are obtained, by 3D-MAX software by the airway images
3D digital figure is converted to, the 3D printing model of novel load medicine airway stent is designed according to the 3D digital figure；Then, it will use
TPU (melt flow index 25g/10min) heating melting prepares 3D printing wire rod；Then, using 3D melt-blown (FDM) printing
The 3D printing wire rod is printed the tube body that is supported by machine；
Accurately weigh the oxaliplatin of 2g, the ibritumomab tiuxetan of 1g, 1g PEG-1000,96g EVA, at 65 DEG C of temperature
Torque rheometer in be blended, prepare drug/high molecular material compound；It in temperature is 70 DEG C by above-mentioned compound
It is hot pressed into hot press cylindric.
Drug/polymer composite is packed into inside the reserving hole of support tube body, obtains novel load medicine airway stent.
Embodiment 5
Firstly, using CT scan patient airway structure, airway images are obtained, by 3D-MAX software by the airway images
3D digital figure is converted to, the 3D printing model of novel load medicine airway stent is designed according to the 3D digital figure；Then, it will use
PCL (melt flow index 20g/10min) heating melting prepares 3D printing wire rod；Then, using 3D melt-blown (FDM) printing
The 3D printing wire rod is printed the tube body that is supported by machine；
The PCL for accurately weighing the taxol of 20g, PEG-1000,79g of 1g, in the torque rheometer of temperature 70 C into
Row is blended, and prepares drug/high molecular material compound；Above-mentioned compound is hot pressed into circle in the hot press that temperature is 80 DEG C
Column.
Drug/polymer composite is packed into inside the reserving hole of support tube body, obtains novel load medicine airway stent.
Embodiment 6
Firstly, using CT scan patient airway structure, airway images are obtained, by 3D-MAX software by the airway images
3D digital figure is converted to, the 3D printing model of novel load medicine airway stent is designed according to the 3D digital figure；Then, it will use
PCL (melt flow index 20g/10min) melting, prepares 3D printing wire rod；It then, will using 3D melt-blown (FDM) printer
The 3D printing wire rod prints the tube body that is supported；
The PCL for accurately weighing the taxol of 5g, the poloxamer188 of 1g, 94g, in the torque rheometer of temperature 70 C
It is blended, prepares drug/high molecular material compound；Above-mentioned compound is hot pressed into the hot press that temperature is 80 DEG C
It is cylindric.
Drug/polymer composite is packed into inside the reserving hole of support tube body, obtains novel load medicine airway stent.
Embodiment 7
Firstly, using CT scan patient airway structure, airway images are obtained, by 3D-MAX software by the airway images
3D digital figure is converted to, the 3D printing model of novel load medicine airway stent is designed according to the 3D digital figure；Then, it will use
PLGA (melt flow index 20g/10min) and PLA (melt flow index 5g/10min) is total by melting after 8:2 mixing
It is mixed, prepare 3D printing wire rod；Then, the 3D printing wire rod is printed by the pipe sheet that is supported using 3D melt-blown (FDM) printer
Body；
Accurately weigh the Aclarubicin of 10g, the alizapride of 2g, 1g PEG-1000,0.5g PLURONICS F87,
The PCL of 86.5g is blended in the torque rheometer of temperature 70 C, prepares drug/polymer composite；It will be above-mentioned compound
Object is hot pressed into cylindric in the hot press that temperature is 70 DEG C.
Drug/polymer composite is packed into inside the reserving hole of support tube body, obtains novel load medicine airway stent.
Embodiment 8
Firstly, using CT scan patient airway structure, airway images are obtained, by 3D-MAX software by the airway images
3D digital figure is converted to, the 3D printing model of novel load medicine airway stent is designed according to the 3D digital figure；Then, it will use
PLGA (melt flow index 20g/10min) and PLA (melt flow index 5g/10min) is total by melting after 8:2 mixing
It is mixed, prepare 3D printing wire rod；Then, the 3D printing wire rod is printed by the pipe sheet that is supported using 3D melt-blown (FDM) printer
Body；
Accurately weigh the Aclarubicin of 10g, the alizapride of 2g, 1g PEG-1000,0.5g PLURONICS F87,
The PCL of 86.5g is blended in the torque rheometer of temperature 70 C, prepares drug/high molecular material compound；It will be upper
State compound temperature be hot pressed into 80 DEG C of hot press it is cylindric.
Drug/polymer composite is packed into inside the reserving hole of support tube body, obtains novel load medicine airway stent.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principles of the present invention,
It should be equivalent substitute mode, be included within the scope of the present invention.
Claims (11)
1. a kind of novel load medicine airway stent, which is characterized in that including supporting tube body, the surface setting of the support tube body
Hole, the inside of described hole are mounted with drug/polymer composite, and the end face design of the support tube body has buckle to tie
Structure；Drug/the polymer composite is grouped as by group as follows by mass percentage: drug 2%-20%, high molecular material
75%-97.8%, dispersing agent 0.2%-5%.
2. novel load medicine airway stent according to claim 1, which is characterized in that the support tube body be " C " type not
Tube closed, with a thickness of 1-3mm.
3. novel load medicine airway stent according to claim 2, which is characterized in that the surface setting of the support tube body
There is the hole being not penetrated, the depth of described hole is the 60%-80% of the support tube body thickness.
4. novel load medicine airway stent according to claim 1, which is characterized in that the support tube body can using biology
Degraded macromolecular material and/or nondegradation high molecular material are prepared；The Biodegradable polymer material is thermoplastic
Property, Biodegradable polymer material；The nondegradation high molecular material is thermoplasticity, nondegradation high molecular material.
5. novel load medicine airway stent according to claim 4, which is characterized in that the Biodegradable polymer material
For one of polylactic acid, polycaprolactone and poly lactide-glycolide acid or at least two mixture；It is described non-degradable
Property high molecular material be polyurethane, ethylene vinyl acetate copolymer, vinyl-acrylate copolymer and ethylene-alpha-olefin copolymerization
One of object.
6. novel load medicine airway stent according to claim 1, which is characterized in that one end setting of the support tube body
There is location hole, the other end of the support tube body is provided with positioning pin, and the positioning pin is inserted into the location hole and forms institute
State buckle structure.
7. novel load medicine airway stent according to claim 1, which is characterized in that the drug/polymer composite
Useful load is the 70%-80% of the volume of described hole.
8. novel load medicine airway stent according to claim 1, which is characterized in that the melting temperature of the high molecular material
Or softening temperature≤70 DEG C, melt flow index >=20g/10min (test temperature: 190 DEG C, load 2.16kg)；The drug
For antitumor platinum class, interference transcription and the drug for preventing RNA from synthesizing, antibiotic, anti-signal transduction medicine, antitumor auxiliary
One of medicine and anti-tumour antibody medicine or at least two mixture；The dispersing agent is polyethylene glycol or/and poloxamer.
9. novel load medicine airway stent according to claim 8, which is characterized in that the high molecular material is ethylene vinyl acetate
Vinyl ester copolymers or polycaprolactone；The antitumor platinum class is preferably oxaliplatin, carboplatin or Nedaplatin；The interference turns
Record process and the drug for preventing RNA from synthesizing are preferably Aclarubicin, Doxorubicin or mitoxantrone；The antibiotic is preferably rich
Lay mycin, bleomycin A5 or mitomycin；The anti-signal transduction medicine be preferably Tarceva, Gefitinib, Imatinib or
Dasatinib；The antitumor adjuvant is preferably alizapride, Azasetron, Ondansetron, chlorine phosphoric acid or mesna；It is described
Anti-tumour antibody medicine is preferably Rituximab, ibritumomab tiuxetan, Cetuximab or bevacizumab.
10. novel load medicine airway stent according to claim 1, which is characterized in that the drug/polymer composite is adopted
It is prepared with the following method: drug 2%-20%, high molecular material 75%-97.8% and dispersing agent 0.2%-5% is mixed
Uniformly, in 60-80 DEG C of progress melt blending, cylindrical body then is hot pressed into 60-85 DEG C；The percentage is mass percent.
11. the preparation method of any one of the claim 1-10 novel load medicine airway stent, which is characterized in that including walking as follows
It is rapid: firstly, scanning patient airway, obtains airway images, the airway images are converted to 3D digitized map by 3D-MAX software
Shape designs the 3D printing model of novel load medicine airway stent according to the 3D digital figure；Then, by polylactic acid drying, heating
Melting prepares 3D printing wire rod；Then, the 3D printing wire rod is printed by the tube body that is supported using 3D melt-blown printer；
Finally, drug/polymer composite to be packed into the inside of the hole of the support tube body, novel load medicine airway stent is obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811123256.6A CN109259908A (en) | 2018-09-26 | 2018-09-26 | A kind of novel load medicine airway stent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811123256.6A CN109259908A (en) | 2018-09-26 | 2018-09-26 | A kind of novel load medicine airway stent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109259908A true CN109259908A (en) | 2019-01-25 |
Family
ID=65197602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811123256.6A Pending CN109259908A (en) | 2018-09-26 | 2018-09-26 | A kind of novel load medicine airway stent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109259908A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112998906A (en) * | 2021-01-25 | 2021-06-22 | 广州睿康医疗科技有限公司 | Multilayer composite structure drug-loaded airway stent and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100122698A1 (en) * | 2008-11-19 | 2010-05-20 | The Nemours Foundation | Neonatal airway stent |
| CN101861132A (en) * | 2007-09-24 | 2010-10-13 | 波士顿科学希姆德公司 | Medical apparatus with the filter insert that is used for controlled spread |
| CN102309368A (en) * | 2010-07-09 | 2012-01-11 | 微创医疗器械(上海)有限公司 | Body lumen drug-carrying bracket and preparation method thereof |
| CN103108663A (en) * | 2010-09-17 | 2013-05-15 | 美敦力瓦斯科尔勒公司 | Apparatus and methods for loading a drug eluting medical device |
| CN104287878A (en) * | 2014-09-16 | 2015-01-21 | 李宝童 | Blood intra-cavity support |
| CN107320217A (en) * | 2017-06-23 | 2017-11-07 | 董念国 | Insertion type valve conveyer |
| CN107822740A (en) * | 2017-10-25 | 2018-03-23 | 中国人民解放军总医院 | Artery medicine elution bracket of biological absorbable material and preparation method thereof |
| CN209790104U (en) * | 2018-09-26 | 2019-12-17 | 广州医科大学 | novel medicine-carrying airway stent |
-
2018
- 2018-09-26 CN CN201811123256.6A patent/CN109259908A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101861132A (en) * | 2007-09-24 | 2010-10-13 | 波士顿科学希姆德公司 | Medical apparatus with the filter insert that is used for controlled spread |
| US20100122698A1 (en) * | 2008-11-19 | 2010-05-20 | The Nemours Foundation | Neonatal airway stent |
| CN102309368A (en) * | 2010-07-09 | 2012-01-11 | 微创医疗器械(上海)有限公司 | Body lumen drug-carrying bracket and preparation method thereof |
| CN103108663A (en) * | 2010-09-17 | 2013-05-15 | 美敦力瓦斯科尔勒公司 | Apparatus and methods for loading a drug eluting medical device |
| CN104287878A (en) * | 2014-09-16 | 2015-01-21 | 李宝童 | Blood intra-cavity support |
| CN107320217A (en) * | 2017-06-23 | 2017-11-07 | 董念国 | Insertion type valve conveyer |
| CN107822740A (en) * | 2017-10-25 | 2018-03-23 | 中国人民解放军总医院 | Artery medicine elution bracket of biological absorbable material and preparation method thereof |
| CN209790104U (en) * | 2018-09-26 | 2019-12-17 | 广州医科大学 | novel medicine-carrying airway stent |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112998906A (en) * | 2021-01-25 | 2021-06-22 | 广州睿康医疗科技有限公司 | Multilayer composite structure drug-loaded airway stent and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stewart et al. | Poly (caprolactone)-based coatings on 3D-printed biodegradable implants: a novel strategy to prolong delivery of hydrophilic drugs | |
| TWI344379B (en) | Alkyd-lactone copolymers for medical applications | |
| CN102933207B (en) | Fast-dissolving solid formulation | |
| Farmer et al. | 3D printed estradiol-eluting urogynecological mesh implants: Influence of material and mesh geometry on their mechanical properties | |
| Claude Desport, Pierre Marie Preux, Cao Tri Truong, Laurent Courat, Jean Michel Vallat, Philippe Couratier | Nutritional assessment and survival in ALS patients | |
| Vergnon et al. | Efficacy of tracheal and bronchial stent placement on respiratory functional tests | |
| JP6869902B2 (en) | Implantable drug delivery composition and its usage | |
| US8895066B2 (en) | Bilayer composition for the sustained release of acetaminophen and tramadol | |
| KR20110117216A (en) | Sustained release oral dosage forms of an r-baclofen prodrug | |
| CN106573015A (en) | Enteric elastomers | |
| AU2006308448A1 (en) | Sustained drug release composition | |
| JP2012504551A (en) | Gastric retention pharmaceutical dosage form | |
| CN105979936A (en) | Pregabalin sustained-release preparation | |
| Schopf et al. | Experimental use of new absorbable tracheal stent | |
| Moroni et al. | Poly (3-hydroxybutyrate): A potential biodegradable excipient for direct 3D printing of pharmaceuticals | |
| CN109259908A (en) | A kind of novel load medicine airway stent and preparation method thereof | |
| Chen et al. | A self-expandable C-shaped 3D printing tracheal stent for combinatorial controlled paclitaxel release and tracheal support | |
| CN209790104U (en) | novel medicine-carrying airway stent | |
| CN109381436A (en) | A Pa is for Buddhist nun's pharmaceutical composition and preparation method thereof | |
| CN109259910A (en) | A kind of multilayer coating film airway stent and preparation method thereof | |
| CN112618505A (en) | Compound pharmaceutical composition containing benazepril and pimobendan for pets and preparation method thereof | |
| CN209595971U (en) | A kind of multilayer coating film airway stent | |
| US20230149299A1 (en) | Implantable and biodegradable drug delivery devices and methods of use thereof | |
| US20230116621A1 (en) | Drug delivery carrier including plga and beta-cyclodextrin containing drug | |
| KR20120131250A (en) | An esophageal stent for controlled delivery of a drug and a preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |